Ovid Application Error
Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy.
Ekert, Henry a; Brizard, Christian b; Eyers, Robert c; Cochrane, Andrew b; Henning, Robert d
Blood Coagulation & Fibrinolysis.
17(5):389-395, July 2006.
(Format: HTML, PDF)